Mark Foletta is an experienced board director/financial executive and currently serves on the board of directors of AMN Healthcare Services and Dexcom. He previously served on board of directors of Regulus Therapeutics, Ambit Biosciences, Anadys Pharmaceuticals, and Viacyte. Mr. Foletta served as Chief Financial Officer of Biocept from 2015 to 2016, and Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from 2000 to August 2012. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. and served as an Audit manager with Ernst & Young. Mr. Foletta received a BA degree in business economics from the University of California, Santa Barbara and is a Certified Public Accountant.